ERBB2 and breast carcinoma: Multiple studies investigating the efficacy of lapatinib in combination with trastuzumab in the neoadjuvant setting for treatment of HER2+ breast cancer have not noted any adverse wound-healing side effects after surgery even with continuing both therapies up until the day of surgery [56].